Forte Biosciences IncNASDAQ:FBRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5500/ 9
- Ask / Lots0.7200/ 1
- Open / Previous Close0.5700 / 0.6000
- Day Range
- 52 Week Range
- Volume13,868
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBRX |
|---|---|---|
| 09:32 ET | 102 | 0.57 |
| 09:39 ET | 833 | 0.57 |
| 09:48 ET | 100 | 0.57 |
| 09:56 ET | 190 | 0.57 |
| 10:01 ET | 1373 | 0.6 |
| 10:55 ET | 1834 | 0.5715 |
| 11:00 ET | 4059 | 0.6 |
| 11:22 ET | 200 | 0.6 |
| 11:51 ET | 200 | 0.61 |
| 02:13 ET | 100 | 0.6001 |
| 03:16 ET | 100 | 0.61 |
| 03:20 ET | 100 | 0.6001 |
| 03:21 ET | 100 | 0.6001 |
| 03:23 ET | 500 | 0.614251 |
| 03:39 ET | 1496 | 0.615 |
| 03:54 ET | 300 | 0.6 |
May 17, 2024
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules, from 4:05PM ET on Friday May 17, 2024 by Dow Jones
4:05PM ET on Friday May 17, 2024 by Dow Jones
May 13, 2024
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones*DJ Forte Biosciences 1Q Loss/Shr 16c >FBRX, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Forte Biosciences Inc | 21.9M | -0.6x | --- |
Cocrystal Pharma Inc | 21.7M | -1.3x | --- |
Neurosense Therapeutics Ltd | 21.5M | -1.5x | --- |
Nymox Pharmaceutical Corp | 21.5M | -4.6x | --- |
NeuroBo Pharmaceuticals Inc | 21.3M | -1.2x | --- |
Indaptus Therapeutics Inc | 21.2M | -1.3x | --- |
Company Information
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Contact Information
- Headquarters
- 3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247
- Phone
- 310-618-6994
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Paul Wagner
- President, Chief Scientific Officer
- Hubert Chen
- Chief Financial Officer
- Antony Riley
- Independent Director
- Scott Brun
- Independent Director
- Stephen Doberstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.03 |
Book Value | $0.97 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
